Fluvoxamine treatment of major depression associated with multiple sclerosis

Francesco Benedetti; Euridice Campori; Cristina Colombo; Enrico Smeraldi

doi:10.1176/jnp.16.3.364

Fluvoxamine treatment of major depression associated with multiple sclerosis

J Neuropsychiatry Clin Neurosci. 2004 Summer;16(3):364-6. doi: 10.1176/jnp.16.3.364.

Authors

Francesco Benedetti¹, Euridice Campori, Cristina Colombo, Enrico Smeraldi

Affiliation

¹ Department of Neuropsychiatric Sciences, Università Vita-Salute San Raffaele, School of Medicine, Milan, Italy. [email protected]

PMID: 15377746
DOI: 10.1176/jnp.16.3.364

Abstract

Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon beta-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.

Publication types

Clinical Trial
Comparative Study

MeSH terms

Adjuvants, Immunologic / therapeutic use
Adult
Depressive Disorder, Major / drug therapy*
Depressive Disorder, Major / etiology*
Drug Administration Schedule
Female
Fluvoxamine / therapeutic use*
Follow-Up Studies
Humans
Interferon beta-1b
Interferon-beta / therapeutic use
Male
Mental Status Schedule
Middle Aged
Multiple Sclerosis / complications*
Selective Serotonin Reuptake Inhibitors / therapeutic use*
Severity of Illness Index
Treatment Outcome

Substances

Adjuvants, Immunologic
Serotonin Uptake Inhibitors
Interferon beta-1b
Interferon-beta
Fluvoxamine